An expert review of data from 79 real-world studies showed that AstraZeneca’s COVID-19 vaccine and the available mRNA COVID-19 vaccines provide equally effective protection against hospitalisation and death from COVID-19 following two doses.1
Data from the VIEW-hub database on vaccine use and impact, developed by Johns Hopkins Bloomberg School of Public Health and the International Vaccine Access Center, was reviewed by infectious disease experts from across Asia. The study findings were reported by Expert Review of Vaccines.
The study shows that the AstraZeneca COVID-19 vaccine and the BNT162b2 and mRNA- 1273 mRNA COVID-19 vaccines offer an equivalent degree of protection against hospitalisation (91-93%) and death (91-93%), regardless of age.1 The data available at the time of review relates to the Delta SARS-Cov-2 and earlier variants, although emerging data on third dose boosting from the UK Health Security Agency and Brazil indicates similar findings on serious COVID-19 outcomes resulting from the Omicron variant.2-4
Professor Guy Thwaites, Director of the Oxford Clinical Research Unit in Vietnam and one of the study’s authors, said: “COVID-19 vaccines have been critical to help save lives and return the world to some normalcy over the past year. Our expert review shows that the AstraZeneca COVID-19 vaccine and available mRNA vaccines provide similar, high-level protection against life-threatening COVID-19. This is important information for policy makers as they consider the optimal deployment of COVID-19 vaccines in their populations over the next 12 months.”
John L. Perez, Senior Vice President, Head of Late Development Vaccines & Immune Therapies Unit, AstraZeneca said: “Real-world data offer crucial insights into the effectiveness of vaccines, including the AstraZeneca COVID-19 vaccine. We are pleased that these data continue to show high-levels of protection against severe clinical outcomes and further our understanding of the important role that vaccination plays in the containment of COVID-19.”
The VIEW-hub platform is updated on a weekly basis to include global real-world studies on vaccine effectiveness. The platform is not currently designed to capture the safety outcomes of these studies, preventing similar safety comparisons.
AstraZeneca and its global partners have released over three billion vaccine doses to more than 180 countries, and approximately two-thirds of these doses have been delivered to low- and lower-middle income countries. Based on model outcomes the AstraZeneca COVID-19 vaccine is estimated to have helped save over 6 million lives between 08 December 2020 and 08 December 2021.5